AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00740896 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking
Description: Active Comparator: Participants smoke 8 cigarettes in 4 hours.
Study NCT00740896 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Smoking
Description: Sham Comparator: Participants are not allowed to smoke for 4 hours.
Study NCT01852799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAD Followed by ASCT
Description: Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)~Drug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)~Drug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)~After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators.
Study NCT01456273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Medical Consultation
Description: Group A will be divided into 2 subgroups : A1- Traditional medical consultation + placebo, and A2- traditional medical consultation plus omeprazole
Study NCT01456273 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Traditional Medical Consultation
Description: Group A will be divided into 2 subgroups : A1- Traditional medical consultation + placebo, and A2- traditional medical consultation plus omeprazole
Study NCT01456273 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Encounter
Description: Group B (who receive care Therapeutic Encounter) will be divided in subgroup B1, which will receive the Drug Therapy Classic and 2 in group B who received placebo.
Study NCT01456273 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Therapeutic Encounter
Description: Group B (who receive care Therapeutic Encounter) will be divided in subgroup B1, which will receive the Drug Therapy Classic and 2 in group B who received placebo.
Study NCT00808431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle counseling
Description: 3 month skills building program emphasizing parent training, behavior modification training, nutrition education, and physical activity promotion
Study NCT04426578 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perhexiline
Description: All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be trough in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated slow metabolisers and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding.~Compliance will be assessed by capsule count.
Study NCT04426578 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: All eligible and consented patients will be randomised to initiation of perhexiline 100mg once daily or identical placebo. After 4 days of treatment, a blood sample will be collected to determine plasma perhexiline concentrations: timing of the sample need not be trough in view of the long-acting nature of perhexiline. Depending on the blood results, patients might require as little as 50mg/week (slow metabolisers) or as much as 600mg/day (ultra-rapid metabolisers). The initial sample will be utilized primarily to detect presence of hydroxylated metabolite: patients in whom perhexiline is detected in the absence of metabolite will be designated slow metabolisers and will have their dosage reduced to 50 mg/week in the first instance. Repeat assay at 30 days will be utilized for individual finer dose titration based on dose adjustment table. Paired dosage adjustment in placebo-treated patients will be performed to avoid unblinding.~Compliance will be assessed by capsule count.
Study NCT03824067 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Point of Care Early Infant Diagnosis
Description: HIV testing where the blood sample is processed at either the facility itself or a nearby site that is closer to the facility than a laboratory. With POC EID, blood samples do not have to travel to the laboratory for processing.
Study NCT00281944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT03556384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Temozolomide 85 mg/m2 will be administered orally for 21 days followed by 7 days without treatment in 28 day cycles.~Treatment will continue for 6 months (with option to continue if benefiting treatment) or until disease progression or unacceptable toxicity (whichever occurs first). All patients will have regular evaluations for assessment of safety parameters
Study NCT03824067 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Early Infant Diagnosis
Description: Conventional laboratory based EID testing
Study NCT02547285 — intervention group
Intervention type: OTHER
Intervention: Shoes characteristics
Description: A single parameter of shoe vary for each test (Different insole, heel height, stem length ...)
Study NCT01522729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Single-dose of intrathecal fentanyl \[25ug\] Duration of fentanyl : 3.5 hours
Study NCT01522729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo comparator
Description: placebo \[NaCl\]
Study NCT00218127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoacetyl Methadol
Description: WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day
Study NCT00218127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoacetyl Methadol
Description: MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)
Study NCT00218127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levoacetyl Methadol
Description: LAAM Fixed Dose evaluation up to 48 mg 48 mg
Study NCT01854931 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Tai Ji Quan
Description: single aim intervention
Study NCT01753739 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bepotastine besilate
Description: Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
Study NCT01753739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
Study NCT00371501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: 10mg/day
Study NCT00371501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet/day
Study NCT00371501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: 80mg/day
Study NCT00371501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT02021656 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LDV/SOF
Description: 90/400 mg FDC tablet administered orally once daily without regard to food
Study NCT04449471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen tablet
Description: For this single intervention arm, each subject will receive a single 220-mg dose of naproxen sodium (Aleve), followed by urine collection for 24-hours.
Study NCT03687970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Pain Inventory
Description: -A self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. The patient is asked to rate their worst, least, average, and current pain intensity (4 items which generate the PAIN SEVERITY score), list current treatments and their perceived effectiveness, and rate the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life (7 items which generate the PAIN INTERFERENCE score) on a 10 point scale.
Study NCT03687970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brief Pain Inventory
Description: -A self-administered questionnaire used to evaluate the severity of a patient's pain and the impact of this pain on the patient's daily functioning. The patient is asked to rate their worst, least, average, and current pain intensity (4 items which generate the PAIN SEVERITY score), list current treatments and their perceived effectiveness, and rate the degree that pain interferes with general activity, mood, walking ability, normal work, relations with other persons, sleep, and enjoyment of life (7 items which generate the PAIN INTERFERENCE score) on a 10 point scale.
Study NCT03687970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Description: * 14 item scale with even of the items relating to anxiety and seven relating to depression~* Each item on the questionnaire is scored from 0-3 and this means that a patient can score between 0 and 21 for either anxiety or depression
Study NCT03687970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hospital Anxiety and Depression Scale
Description: * 14 item scale with even of the items relating to anxiety and seven relating to depression~* Each item on the questionnaire is scored from 0-3 and this means that a patient can score between 0 and 21 for either anxiety or depression
Study NCT03687970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropathic Pain Symptom Inventory
Description: -The NPSI questionnaire utilized in this study includes eight parameters (i.e., burning pain, squeezing pain, pressure pain, electric shock pain, stabbing pain, tingling pain, pins and needles pain and allodynia \[pain provoked by light touch\]). Each of the parameters includes recall of the past 24 hours
Study NCT03687970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropathic Pain Symptom Inventory
Description: -The NPSI questionnaire utilized in this study includes eight parameters (i.e., burning pain, squeezing pain, pressure pain, electric shock pain, stabbing pain, tingling pain, pins and needles pain and allodynia \[pain provoked by light touch\]). Each of the parameters includes recall of the past 24 hours
Study NCT03687970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Diode Laser fiber type Selective Stimulator
Description: -Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fibers
Study NCT03687970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Diode Laser fiber type Selective Stimulator
Description: -Each patient will have an A and C fiber stimulation. Stimulation will be performed on the dorsum of the foot using stimulation previously published parameters to elicit burning pain, which is from activation of C-fibers and pinprick pain from A-fibers
Study NCT03687970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing
Description: * Quantitative sensory testing will be performed on the dorsal mid-foot and the ipsilateral shoulder will serve as control area~* Cold and warm detection thresholds, cold and heat pain thresholds, mechanical detection thresholds, and wind-up ratio
Study NCT03687970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative sensory testing
Description: * Quantitative sensory testing will be performed on the dorsal mid-foot and the ipsilateral shoulder will serve as control area~* Cold and warm detection thresholds, cold and heat pain thresholds, mechanical detection thresholds, and wind-up ratio
Study NCT03687970 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conditioned pain modulation efficiency
Description: -Immersion of a hand up to the wrist to a thermostat-controlled water bath maintained at 12 degrees Celsius, and the application of a heat stimulus on the contralateral forearm.
Study NCT03687970 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conditioned pain modulation efficiency
Description: -Immersion of a hand up to the wrist to a thermostat-controlled water bath maintained at 12 degrees Celsius, and the application of a heat stimulus on the contralateral forearm.
Study NCT03687970 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)
Description: -The subjects are asked to rate the intensity of their current pain on a 0-10 scale - 0 denoting no pain and 10 denoting worst imaginable pain.
Study NCT03687970 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous pain at baseline on 0-10 Numerical Rating Scale (NRS)
Description: -The subjects are asked to rate the intensity of their current pain on a 0-10 scale - 0 denoting no pain and 10 denoting worst imaginable pain.
Study NCT01952470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dornase Alfa
Description: Once daily, 2.5ml inhaled dornase alfa (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Study NCT01952470 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic Saline.
Description: Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
Study NCT02059005 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specialized Community Disease Management
Description: Specialized Community Disease Management is 90-day program that employs specialized teams including a trained clinical social worker and a peer-specialist community health worker who provide evidence-based telephone continuing care, home visits, and focus on patients' substance use following hospital discharge.
Study NCT02059005 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment As Usual
Description: Treatment as Usual is a 90-day, post-discharge program that consists of medical monitoring by nurses and community health workers who have no special training in working with substance use disorder patients, and does not address substance use.
Study NCT02561624 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behaviour change communication via text message
Study NCT01594385 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Seprafilm
Description: Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:~* Two Seprafilm pieces between the liver and the anterior abdominal wall~* Four pieces over the exposed bowel surfaces anteriorly~* Two slightly staggered pieces of Seprafilm in each colic gutter~* Two pieces in the pelvic area.~* If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair.
Study NCT02276573 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: buccal cavity sample
Study NCT04071587 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Computer Interface training
Description: Training with RecoveriX system.
Study NCT04071587 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard physiotherapy and occupational therapy according to clinical routines.
Study NCT00867477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breathing Test
Description: Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).
Study NCT00867477 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory Symptoms Questionnaire
Description: 3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.
Study NCT00867477 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pet Scan
Description: Between 40 and 50 days after the end of the radiation therapy. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility.
Study NCT01764802 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: behavioral, psychological or informational intervention
Description: Participate in enhanced standard care
Study NCT01764802 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: behavioral, psychological or informational intervention
Description: Participate in psychological intervention
Study NCT02734433 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Study NCT01683773 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AERAS-402
Description: Intramuscular needle injection 1x10\^11 vp
Study NCT03163160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor manual therapy group
Description: Soft-tissue (myofascial) stretching techniques on pelvic floor muscles through external and internal (intra-vaginal) mobilizations. One weekly session for four weeks.
Study NCT03163160 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic floor electrolysis group
Description: An ultrasound-guided application of a galvanic electrolytic current with an acupuncture needle in the soft tissue of pelvic floor. EPI technique was applied using a specifically device (EPI-X Omega Advanced Medicine, Barcelona, Spain) which produces modulated galvanic electricity. This is applied using a modified electrosurgical scalpel that incorporates acupuncture needles (0.3 mm in diameter) of different lengths. The intensity can be adjusted by changing either the duration of stimulation or the output current (mA) of the device.~One weekly session for four weeks.
Study NCT01559727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
Study NCT01559727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
Study NCT01559727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
Study NCT00281944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00281944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00281944 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00258687 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX
Description: 4 vaccines every two weeks
Study NCT00690495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol (drug), intravenous, induction of anesthesia
Study NCT00690495 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol 1%
Description: Propofol (drug), intravenous, induction of anesthesia
Study NCT00281944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Undergo PET scan
Study NCT00281944 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo PET/CT scan
Study NCT02303743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Smart Phone Application
Description: Bowel preparation was evaluated using the Harefield Cleansing Scale (HCS). The scale was the primary outcome measure
Study NCT01361633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: d-cycloserine
Description: single oral administration of 250 mg d-cycloserine
Study NCT01361633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar Pill
Description: Single oral administration 250 mg Sugar Pill
Study NCT00558402 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Meditation
Description: meditation class 1/week for 8 weeks
Study NCT00558402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education
Description: Education class, 90 min per week for 8 weeks along with home assignments based on Powerful Tools for Caregivers
Study NCT00558402 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Respite only
Description: Respite care 90 mins per week for 8 weeks
Study NCT02303743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Written instructions with visual aids
Description: written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution (control group).
Study NCT01839643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam 2.4 g
Description: 2.4 g in Vaginal Ring